Literature DB >> 26620676

CD4 T cell knockout does not protect against kidney injury and worsens cancer.

Kameswaran Ravichandran1, Qian Wang1, Abdullah Ozkok1, Alkesh Jani1, Howard Li1, Zhibin He1, Danica Ljubanovic2, Mary C Weiser-Evans1, Raphael A Nemenoff1, Charles L Edelstein3.   

Abstract

UNLABELLED: Most previous studies of cisplatin-induced acute kidney injury (AKI) have been in models of acute, high-dose cisplatin administration that leads to mortality in non-tumor-bearing mice. The aim of the study was to determine whether CD4 T cell knockout protects against AKI and cancer in a clinically relevant model of low-dose cisplatin-induced AKI in mice with cancer. Kidney function, serum neutrophil gelatinase-associated lipocalin (NGAL), acute tubular necrosis (ATN), and tubular apoptosis score were the same in wild-type and CD4 -/- mice with AKI. The lack of protection against AKI in CD4 -/- mice was associated with an increase in extracellular signal-regulated kinase (ERK), p38, CXCL1, and TNF-α, mediators of AKI and fibrosis, in both cisplatin-treated CD4 -/- mice and wild-type mice. The lack of protection was independent of the presence of cancer or not. Tumor size was double, and cisplatin had an impaired therapeutic effect on the tumors in CD4 -/- vs. wild-type mice. Mice depleted of CD4 T cells using the GK1.5 antibody were not protected against AKI and had larger tumors and lesser response to cisplatin. In summary, in a clinically relevant model of cisplatin-induced AKI in mice with cancer, (1) CD4 -/- mice were not protected against AKI; (2) ERK, p38, CXCL1, and TNF-α, known mediators of AKI, and interstitial fibrosis were increased in CD4 -/- kidneys; and (3) CD4 -/- mice had faster tumor growth and an impaired therapeutic effect of cisplatin on the tumors. The data warns against the use of CD4 T cell inhibition to attenuate cisplatin-induced AKI in patients with cancer. KEY MESSAGE: A clinically relevant low-dose cisplatin model of AKI in mice with cancer was used. CD4 -/- mice were not functionally or histologically protected against AKI. CD4 -/- mice had faster tumor growth. CD4 -/- mice had an impaired therapeutic effect of cisplatin on the tumors. Mice depleted of CD4 T cells were not protected against AKI and had larger tumors.

Entities:  

Keywords:  CD4 T cell; Cancer; Kidney

Mesh:

Substances:

Year:  2015        PMID: 26620676     DOI: 10.1007/s00109-015-1366-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  30 in total

1.  Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis.

Authors:  Belda Dursun; Zhibin He; Hilary Somerset; Dong-Jin Oh; Sarah Faubel; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2006-04-18

2.  Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat.

Authors:  Glenda Gobé; Xiao-Ju Zhang; Desley A Willgoss; Estelle Schoch; Nicole A Hogg; Zoltán H Endre
Journal:  J Am Soc Nephrol       Date:  2000-03       Impact factor: 10.121

3.  IL-33 exacerbates acute kidney injury.

Authors:  Ali Akcay; Quocan Nguyen; Zhibin He; Kultigin Turkmen; Dong Won Lee; Ana Andres Hernando; Christopher Altmann; Aysun Toker; Arijana Pacic; Danica Galesic Ljubanovic; Alkesh Jani; Sarah Faubel; Charles L Edelstein
Journal:  J Am Soc Nephrol       Date:  2011-09-23       Impact factor: 10.121

4.  Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

Authors:  Meredith A Tennis; Michelle Van Scoyk; Lynn E Heasley; Katherine Vandervest; Mary Weiser-Evans; Scott Freeman; Robert L Keith; Pete Simpson; Raphael A Nemenoff; Robert A Winn
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

5.  Morphometric and visual evaluation of fibrosis in renal biopsies.

Authors:  Alton B Farris; Catherine D Adams; Nicole Brousaides; Patricia A Della Pelle; A Bernard Collins; Ellie Moradi; R Neal Smith; Paul C Grimm; Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

6.  CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice.

Authors:  Hyojung Lee; Dukhee Nho; Hwan-Suck Chung; Heekyung Lee; Min-Kyu Shin; Sung-Hoon Kim; Hyunsu Bae
Journal:  Kidney Int       Date:  2010-05-12       Impact factor: 10.612

7.  Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis.

Authors:  Sarah Faubel; Danica Ljubanovic; Leonid Reznikov; Hilary Somerset; Charles A Dinarello; Charles L Edelstein
Journal:  Kidney Int       Date:  2004-12       Impact factor: 10.612

8.  p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.

Authors:  Ganesan Ramesh; W Brian Reeves
Journal:  Am J Physiol Renal Physiol       Date:  2005-02-08

9.  TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells.

Authors:  Giulia Benedetti; Lisa Fredriksson; Bram Herpers; John Meerman; Bob van de Water; Marjo de Graauw
Journal:  Biochem Pharmacol       Date:  2012-10-24       Impact factor: 5.858

10.  Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice.

Authors:  Lawrence H Lu; Dong-Jin Oh; Belda Dursun; Zhibin He; Thomas S Hoke; Sarah Faubel; Charles L Edelstein
Journal:  J Pharmacol Exp Ther       Date:  2007-10-11       Impact factor: 4.030

View more
  18 in total

Review 1.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

2.  Cisplatin nephrotoxicity as a model of chronic kidney disease.

Authors:  Mingjun Shi; Kathryn L McMillan; Junxia Wu; Nancy Gillings; Brianna Flores; Orson W Moe; Ming Chang Hu
Journal:  Lab Invest       Date:  2018-06-01       Impact factor: 5.662

Review 3.  Rodent models of AKI-CKD transition.

Authors:  Ying Fu; Chengyuan Tang; Juan Cai; Guochun Chen; Dongshan Zhang; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2018-06-27

Review 4.  Bridging translation for acute kidney injury with better preclinical modeling of human disease.

Authors:  Nataliya I Skrypnyk; Leah J Siskind; Sarah Faubel; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

Review 5.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

6.  Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration.

Authors:  Cierra N Sharp; Mark Doll; Tess V Dupre; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-28

7.  C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.

Authors:  Sophia M Sears; Cierra N Sharp; Austin Krueger; Gabrielle B Oropilla; Douglas Saforo; Mark A Doll; Judit Megyesi; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-24

8.  The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice.

Authors:  Carolyn N Brown; Daniel J Atwood; Deepak Pokhrel; Kameswaran Ravichandran; Sara J Holditch; Sanskriti Saxena; Makoto Miyazaki; Raphael Nemenoff; Mary C M Weiser-Evans; Danica Galesic Ljubanovic; Melanie S Joy; Charles L Edelstein
Journal:  Cell Signal       Date:  2020-03-16       Impact factor: 4.315

9.  Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease.

Authors:  Cierra N Sharp; Mark A Doll; Judit Megyesi; Gabrielle B Oropilla; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-31

10.  IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer.

Authors:  Kameswaran Ravichandran; Sara Holditch; Carolyn N Brown; Qian Wang; Abdullah Ozkok; Mary C Weiser-Evans; Raphael Nemenoff; Makoto Miyazaki; Heather Thiessen-Philbrook; Chirag R Parikh; Danica Ljubanovic; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.